Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
Six months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) appears to be noninferior to 12 months of therapy, according to an industry-supported, noninferiority study in The BMJ.
Researchers enrolled adults who began DAPT after placement of second-generation drug-eluting stents following STEMI. At 6 months, nearly 900 patients who were event-free were randomized to continue DAPT for another 6 months or switch to aspirin alone.
At 24 months after initial PCI, the primary composite endpoint — all-cause mortality, MI, revascularization, stroke, or thrombolysis in myocardial infarction major bleeding — occurred in 4.8% of those who received 6 months of DAPT and 6.6% who received 12 months.
The authors conclude: "While larger trials have shown that longer duration of DAPT regimens might be associated with favourable ischaemic outcomes, this trial for the first time shows that a shorter DAPT duration is also feasible and safely applicable if clinically required even in patients with STEMI."
Comment
LINK(S):
The BMJ article (Free)
Background: Physician's First Watch coverage of prolonged DAPT after PCI (Free)